Tamer Othman, M.D.
Acute lymphoblastic leukemia
Acute myeloid leukemia
Myelodysplastic syndromes
Hematopoietic Cell Transplantation (HCT)
CAR T-cell therapy
Assistant Clinical Professor
Tamer Othman, M.D., is an assistant clinical professor specializing in leukemia and hematopoietic cell transplantation at City of Hope® Orange County's Lennar Foundation Cancer Center and Cancer Specialty Hospital. His clinical expertise focuses on the diagnosis and treatment of acute leukemias, particularly acute lymphoblastic leukemia (ALL), with an emphasis on integrating novel immunotherapies, targeted therapies, and cellular therapies into patient care.
Dr. Othman's research focuses on improving outcomes for patients with ALL through the development and optimization of treatment strategies. His work explores the clinical application of novel immunotherapies, mechanisms of treatment resistance and relapse, molecular predictors of treatment response, and strategies to reduce treatment-related toxicity. He has a particular interest in advancing personalized approaches to leukemia treatment and expanding the role of cellular therapies, including chimeric antigen receptor (CAR) T-cell therapy and hematopoietic cell transplantation. His research has been published in numerous peer-reviewed medical journals.
Dr. Othman earned his medical degree from Rush Medical College and completed his internal medicine residency at Harbor-UCLA Medical Center. He subsequently completed his hematology and oncology fellowship at UC Davis Medical Center, followed by advanced fellowship training in hematopoietic cell transplantation and cellular therapy at City of Hope.
Committed to advancing leukemia care through both clinical practice and research, Dr. Othman strives to translate scientific discoveries into more effective, individualized treatment options. He believes in building strong relationships with patients and their families through compassionate care, open communication, and shared decision-making.
Location
Orange County Cancer Specialty Hospital
Irvine, CA 92618
Orange County Lennar Foundation Cancer Center
Irvine, CA 92618
Education & Experience
Board Certifications
2022, American Board of Internal Medicine, Hematology
2020, American Board of Internal Medicine, Internal Medicine
2018, Medical Board of California Physician and Surgeon License, A158324
Degrees
- 2017, Doctor of Medicine, Rush Medical College, Chicago, IL
- 2012, Bachelor of Science, Summa Cum Laude, Neurobiology, Physiology and Behavior, University of California Davis, Davis, CA
Fellowship
- 2023-2024, Hematopoietic Cell Transplantation and Cellular Therapy Fellowship, City of Hope Cancer Center Duarte, Duarte, CA
- 2020-2023, Hematology/Oncology Fellowship, University of California Davis Medical Center, Sacramento, CA
Residency
- 2017-2020, Internal Medicine Residency, Harbor-UCLA Medical Center, Torrance, CA
Professional Experience
- 2025-Present, Assistant Clinical Professor, City of Hope Orange County Lennar Foundation Cancer Center, Irvine, CA
- 2024-2025, Assistant Clinical Professor, University of California San Francisco, San Francisco, CA
Awards & Memberships
Awards
2025, ASTCT Clinical Research Training Course
2024, 3rd Annual City of Hope – Graduate Medical Education Academic Excellence Day, Best Oral Presentation
2023, City of Hope Dr. Kathy Wishner Travel Award
2023, University of California Davis Department of Internal Medicine John C. Rutledge Trainee Research Award
- 2022-2023, FDA-AACR Oncology Educational Fellowship
- 2022, Association of Northern California Oncologists Travel Award
Memberships
- 2011-present, Member, International Association for the Study of Lung Cancer
- 2010-present, Member, Society of Thoracic Surgeons
Publications
Publications
- Othman T#, Baird JH#, Wang Y, Pak S, Zhong H, Aldoss I, Cai J, Danilov A, Phillips TJ, Agrawal V, Sandhu KS, Mei M, Koller PB, Palmer J, Forman SJ, Budde LE, Aribi A. Outpatient Brexucabtagene Autoleucel in B-cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma. Accepted in Am J Hematol. In-press. #Contributed equally
- Muhsen IN, Roloff GW, Faramand RG, Othman T, Valtis YK, Kopmar NE, Dekker SE, Connor M, Mercadal S, O'Connor TE, Dykes KC, Ahmed M, Jeyakumar N, Zhang A, Miller K, Sutherland KC, Guzowski C, Gupta VK, Majhail NS, Battiwalla M, Solh MM, Malik SA, Mathews J, Oliai C, Shaughnessy PJ, Mountjoy L, Lee CJ, Logan AC, Tsai SB, Leonard JT, Schwartz MS, Sasine JP, Kumaran M, Frey NV, Park JH, Koura D, Cassaday RD, Shah BD, Aldoss I, Muffly LS, Hill LC. Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement. Blood Adv. 2025 May 7:bloodadvances.2024015779. Epub ahead of print. PMID: 40334068.
- Chehrazi-Raffle A, Zugman M, Ebrahimi H, Shodiya MO, Maldonado E, Othman T, Jaime- Casas S, Barragan-Carrillo R, Li X, Pal SK, Tripathi A, Zhumkhawala A, Hoeg R, Oliai C, Olin RL, Dorff TB, Mei M. Multicenter analysis of high-dose chemotherapy regimens for the treatment of patients with refractory or recurrent germ cell tumors. ESMO Open. 2025 May;10(5):105081. Epub 2025 May 1. PMID: 40315659.
- Othman T, Lo MM, Andreadis CB, Damon LE, Ferng TT, Gaensler KML, Lee JC, Martin TG, Olin RL, Sayre PH, Smith CC, Logan AC. Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. Leuk Lymphoma. 2025 May 7:1-4. Epub ahead of print. PMID: 40329916.
- Lust H, Schultz LM, Kwon S, Roloff GW, Aldoss I, Baggott C, John S, Rossoff J, McNerney KO, Fabrizio VA, Talano JA, Moskop A, Curran KJ, Phillips CL, Karras NA, Baumeister SHC, Cooper S, Hermiston ML, Satwani P, Qayed M, Raikar SS, MacMillan ML, Hall EM, Nguyen K, Cassaday RD, Kopmar NE, Kota VK, Mathews J, Shaughnessy PJ, Schwartz MS, Ladha A, Yaghmour G, Kumaran M, Bachanova V, Tracy SI, Othman T, Luskin MR, Chen EC, Advani AS, Jeyakumar N, Miller K, Zhang A, Shah BD, Muffly LS, Faramand RG. Real World Outcomes for Young Adult Patients Receiving CD19 CAR T-cell Therapy. Blood Adv. 2025 Mar 24:bloodadvances.2024014846. Epub ahead of print. PMID: 40127395.
- Koller PB# , Othman T#, Yang D, Mokhtari S, Samara Y, Blackmon A, Agrawal V, Pourhassan H, Ball BJ, Amanam I, Arslan S, Otoukesh S, Sandhu KS, Aldoss I, Ali H, Salhotra A, Aribi A, Artz A, Becker PS, Pullarkat V, Stewart FM, Smith EP, Stein A, Marcucci G, Forman SJ, Nakamura R, Al Malki MM. Melphalan-based conditioning with post- transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect. Bone Marrow Transplant. 2025 May;60(5):625-631. PMID: 40016513. #Contributed equally
- Othman T, Marquez-Arreguin G, Esteghamat N, Tuscano J. A phase I trial of CC-486, lenalidomide, obinutuzumab in relapsed/refractory indolent non-Hodgkin lymphoma. Leuk Lymphoma. 2025 May;66(5):961-964. PMID: 39731545.
- Othman T, Logan AC, Muffly L, Leonard J, Park J, Shah B, Aldoss I. The Role of CAR T- Cell Therapy in Relapsed/Refractory Adult B-ALL. J Natl Compr Canc Netw. 2024 Oct;22(8):e247065. PMID: 39413830.
- Rahman ZA# , Othman T#, Saliba RM, Vanegas YAM, Mohty R, Ledesma C, Rondon G, Jain N, Jabbour E, Pullarkat V, Alkhateeb HB, Kantarjian HM, Greipp PT, Nakamura R, Kharfan- Dabaja MA, Champlin RE, Forman SJ, Shpall EJ, Litzow MR, Foran JM, Aldoss I, Koller PB, Kebriaei P. A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission. Transplant Cell Ther. 2024 Dec;30(12):1197-1205. PMID: 39332807 #Contributed equally
- Badar T, Narra R, Mims AS, Heckman MG, Shallis RM, Fahad S, Hunter C, Kota V, Othman TA, Jonas B, Desai S, de Camargo Correia GS, Patel A, DuVall AS, Palmisiano N, Curran E, Omer Z, Advani A, Atallah E, Litzow M. Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome- positive acute lymphoblastic leukemia: A multi-institutional study. Am J Hematol. 2024 Dec;99(12):2388-2391. PMID: 39253997
- Othman T, Frankel P, Allen P, Popplewell LL, Shouse G, Siddiqi T, Danilov AV, Ruel N, Daniels S, Peters L, Khoo S, Rosen ST, Sharon E, Villalona-Calero M, Ruel C, Tuscano J, Herrera AF. Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma. Haematologica. 2025 Jan 1;110(1):142-152. PMID: 39021209.
- Othman T, Koller P, Pourhassan H, Agrawal V, Ngo D, Tinajero J, Ali H, Cai JL, Mei M, Aribi A, Stein AS, Marcucci G, Forman SJ, Pullarkat V, Aldoss I. Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol. 2024 Aug;205(2):711- 715. PMID: 38808512.
- Othman T#, Koller P#, Tsai NC, Yang D, Pourhassan H, Agrawal V, Ngo D, Chen J, Farol L, Spielberger R, Sahebi F, Al Malki MM, Cai JL, Sandhu KS, Mansour J, Salhotra A, Ali H, Aribi A, Arslan S, Marcucci G, Forman SJ, Stein AS, Nakamura R, Pullarkat V, Aldoss I, Mei M. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2024 Sep;99(9):1680-1690. PMID: 38804599. #Contributed equally
- Othman T, Li S, Zhang J, Pourhassan H, Agrawal V, Ngo D, Chen J, Farol L, Sahebi F, Sandhu K, Spielberger R, Marcucci G, Forman SJ, Stein AS, Nakamura R, Pullarkat V, Mei M, Aldoss I, Koller P. Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2024 Aug;99(8):1636-1639. PMID: 38800943.
- Othman T#, Baird JH#, Pak S, Mei M, Herrera AF, Mansour J, Shouse G, Sahebi F, Spielberger R, Cai JL, Farol L, Godfrey J, Kallam A, Phillips T, Popplewell L, Siddiqi T, Forman S, Budde LE. Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma. Br J Haematol. 2024 Jul;205(1):368-372. PMID: 38797530. #Contributed equally
- Othman T, Lowsky R, Richman C, Hoeg R, Abedi M, Tuscano J. Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma. Bone Marrow Transplant. 2023 Oct;58(10):1143-1145. PMID: 37391654.
- Othman T, Quan MA, Zhang S, Gaut D, Young PA, Mahmood O, Abdulhaq H, Shieh K, Reid J, Brem EA, Hariharan N, Heyman B, Tuscano J. Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):749-756. PMID: 37336714.
- Othman T, Penaloza J, Zhang S, Daniel CE, Gaut D, Oliai C, Brem EA, Baweja A, Ly J, Reid J, Pinter-Brown L, Lee M, Abdulhaq H, Tuscano J. R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2022 Oct;22(10):e947- e957. PMID: 35858904.
- Othman T#, Moskoff BN#, Ho G, Tenold ME, Azenkot T, Krackeler ML, Fisch SC, Potter LA, Kaesberg PR, Welborn JL, Wun T, Esteghamat NS, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center. Leuk Res. 2022 Aug;119:106885. PMID: 35738024. #Contributed equally